|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|||||||||||||||
| Dermatology Regina C. Hamlin, MD |
|||
|
Clinical
Professor of Medicine Associate Clinical Professor of Dermatology |
|||
| Medical School: | University of California, San Francisco | |
| Residency: | University of California, San Francisco | |
| Board Certified: | Dermatology Forensic Medicine |
|
| Awards and Recognition: | Medical Director,
Associates in Research, Inc Formerly Medical Director, Hill Top Research |
| Current Research: | |||
| 1.
2001, Principal Investigator, "A Phase II Randomized, Double-
blind, Placebo-ControlJed Study of XXX-XXX, A Humanized Monoclonal Antibody that Binds to the XXX-XXX, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis 2001, Sub-Investigator, A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of XXX @ (XXX) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders 2. 2001, Sub-Investigator, A Phase IV, A randomized comparator, controlled, double-blind, study of the liver safety of XXX XXX versus XXX with XXX and insulin as part of step therapy in subjects with type 2 (non-insulin dependent) diabetes. 3. 2001, Sub-Investigator, A Phase II Randomized, Double-blind, Placebo-Controlled Study of XXX, A Humanized Monoclonal Antibody that Binds to the XX XXX, Administered by Intravenous Infusion to Adults with Plaque Psoriasis 4. 2001, Sub-Investigator, "A Phase II, Randomized, Double Blind Parallel Group Pilot Study to Evaluate the Safety and Efficacy of XXX in Patients with Uterine Leiomyomata". 5. 2001, Sub-Investigator, "A Phase II, Long Term Extension Safety Study of XXX (XX mg) Administered with XXX to Post-Menopausal Women" 6. 2001, Principal Investigator, A Phase II Randomized, Double-blind, Placebo-Controlled Study of XXX, A Humanized Monoclonal Antibody that Binds to the XXX Receptor, Administered by Intravenous Infusion to Adults with Plaque Psoriasis 7. 2001, Principal Investigator, Phase III Vehicle-Controlled, Double- Blind Study to Assess the Safety and Efficacy of XXX 5% Cream for the Treatment of Superficial Basal Cell Carcinoma 8. 2000, Sub-investigator, Phase II1 A Comparative Study of the Safety and Efficacy of XXX, 150 mg ODD for 5 Days and XXX 250 mg X xx oD for Day 1, XXX 250mg QD for Days 2-5, for the Treatment of Subjects with Acute Bacterial Exacerbation of Chronic Bronchitis 8. 2000, Sub-Investigator, A Phase III study, An open Non- Competitive Trail with XXX, XXX 300mg PO BID for Seven Days in the Treatment of Acute Bacterial Sinusitis in Conjunction with Antral Sinus Aspirations for Diagnostic Microbiology 9. 2000, Principal Investigator, "A Phase III Double-Blind efficacy and Safety Study of XXX (10mg) in Addition to XXX Compared to Placebo in Subjects with Primary Hypercholesterolemia" 10. 2000, Sub-Investigator, "A Phase III Double-Blind, Placebo- controlled, Randomized, Multi-center Study to Investigate the Efficacy and Safety of XXX in Non-Constipated Patients with Established Bowel Syndrome" 11. 2000, Sub-Investigator, "A Phase II Pilot Study to Evaluate the Safety and Efficacy of X XXX Administered With XXX to Post- Menopausal Women" 12. 2000 Principal Investigator, Phase IV Open Label Pilot Study of XXX ( XXX) 5% Cream for the Treatment of Warts ( Common and Flat Warts) in Children and Adults 13. 2000, Principal Investigator," A Phase III Randomized, Double- Blind, Placebo-Controlled, Dose-Comparison Study to Evaluate the Efficacy and Safety of Intramuscular Administration of XXX (XXX, XXX XXX XXX) in Subjects with Chronic Plaque Psoriasis" 14. 2000, Principal Investigator, "A Phase II Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple dose Clinical Trial of XXX-XXX in Patients with Moderate to Severe Plaque Psoriasis" |
|||
